Pfizer Inc (PFIZ34) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pfizer Inc (PFIZ34) has a cash flow conversion efficiency ratio of 0.029x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (R$2.62 Billion ≈ $513.11 Million USD) by net assets (R$90.40 Billion ≈ $17.74 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Pfizer Inc to measure how many days the company can operate on defensive assets alone.
Pfizer Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Pfizer Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pfizer Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pfizer Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pfizer Inc
NYSE:PFE
|
0.029x |
|
Banco Santander S.A
F:BSDK
|
0.080x |
|
Schneider Electric S.E.
PA:SU
|
0.202x |
|
Siemens Energy AG
F:ENR
|
0.272x |
|
Applovin Corp
NASDAQ:APP
|
0.546x |
|
Uber Technologies Inc
NYSE:UBER
|
0.103x |
|
Welltower Inc
NYSE:WELL
|
0.015x |
|
Honeywell International Inc
NASDAQ:HON
|
0.076x |
Annual Cash Flow Conversion Efficiency for Pfizer Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Pfizer Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Pfizer Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | R$86.78 Billion ≈ $17.03 Billion |
R$11.71 Billion ≈ $2.30 Billion |
0.135x | -6.33% |
| 2024-12-31 | R$88.50 Billion ≈ $17.36 Billion |
R$12.74 Billion ≈ $2.50 Billion |
0.144x | +6.78% |
| 2023-12-31 | R$89.29 Billion ≈ $17.52 Billion |
R$12.04 Billion ≈ $2.36 Billion |
0.135x | -55.92% |
| 2022-12-31 | R$95.66 Billion ≈ $18.77 Billion |
R$29.27 Billion ≈ $5.74 Billion |
0.306x | -27.50% |
| 2021-12-31 | R$77.20 Billion ≈ $15.15 Billion |
R$32.58 Billion ≈ $6.39 Billion |
0.422x | +85.29% |
| 2020-12-31 | R$63.24 Billion ≈ $12.41 Billion |
R$14.40 Billion ≈ $2.83 Billion |
0.228x | +14.26% |
| 2019-12-31 | R$63.14 Billion ≈ $12.39 Billion |
R$12.59 Billion ≈ $2.47 Billion |
0.199x | -20.14% |
| 2018-12-31 | R$63.41 Billion ≈ $12.44 Billion |
R$15.83 Billion ≈ $3.11 Billion |
0.250x | +5.93% |
| 2017-12-31 | R$71.31 Billion ≈ $13.99 Billion |
R$16.80 Billion ≈ $3.30 Billion |
0.236x | -13.36% |
| 2016-12-31 | R$59.54 Billion ≈ $11.68 Billion |
R$16.19 Billion ≈ $3.18 Billion |
0.272x | +20.34% |
| 2015-12-31 | R$65.00 Billion ≈ $12.75 Billion |
R$14.69 Billion ≈ $2.88 Billion |
0.226x | -5.26% |
| 2014-12-31 | R$71.62 Billion ≈ $14.05 Billion |
R$17.08 Billion ≈ $3.35 Billion |
0.239x | -- |
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevna… Read more